SOURCE: Entelos, Inc.

August 17, 2005 12:13 ET

Entelos to Develop Computer Model of Skin Sensitization With Unilever

Development of New Approaches for Assuring the Safety of Consumer Products

FOSTER CITY, CA -- (MARKET WIRE) -- August 17, 2005 -- Entelos, Inc. announced today that it has entered into collaboration with Unilever to develop an in silico (computer simulation) model for the study of skin allergy (sensitization) -- the "Skin Sensitization PhysioLab platform." As part of the agreement, Entelos will transfer the technology to Unilever for continued advancement of the model and research in skin sensitization. Entelos will retain full rights to use the platform, including rights for all pharmaceutical applications. Financial terms of the collaboration were not disclosed.

This work forms part of an on-going Unilever program to develop alternative approaches for risk assessment for assuring the safety of consumer products.

The Skin Sensitization PhysioLab platform will benefit from Entelos' previous experience in developing and applying computer simulation of disease in human beings. The platform will represent the dynamics of skin sensitization, and be used to identify the biological drivers of its induction. This research provides a unique systems biology approach that is expected to provide new insights for the future development of the next generation of tests and new approaches for risk assessment.

"This collaboration continues to demonstrate the broad applicability of the PhysioLab technology throughout the health and personal care industries," stated James Karis, President and CEO of Entelos. "We have established the technology in the context of predicting human response to therapeutic interventions, and are now taking our first steps to demonstrate the use of the technology in predicting human safety. We are extremely pleased to be collaborating with Unilever and look forward to a productive and successful collaboration."

Bart Sangster, Senior Vice President, Safety & Environmental Assurance for Unilever, said, "We're very pleased to add this initiative to Unilever's on-going effort to develop novel ways of delivering consumer safety."

About Unilever

Unilever, one of the world's largest consumer products companies, adds vitality to life by meeting the everyday needs for nutrition, hygiene and personal care. With a portfolio of great brands that make people feel good, look good and get more out of life, 150 million consumers around the world choose Unilever products every day, including icons such as: Hellmann's, Lipton, Dove, Rexona, Wisk, Skippy, Breyer's, Axe and Suave.

Unilever has 223,000 employees in around 100 countries and generated annual sales of EUR 42 billion in 2004. For more information about Unilever and its brands, please visit

About Entelos

Entelos, Inc. ( is a biopharmaceutical company focused on discovering and developing new therapies for metabolic and inflammatory disorders. Our mission is to leverage our unique predictive capability in human biology to dramatically improve how medicines are discovered, developed, and brought to market. Using our proprietary PhysioLab biosimulation platforms -- computer-based mathematical models of human disease, we systematically uncover the biological mechanisms underlying a disease in order to identify potential points of therapeutic intervention and the patients most likely to benefit. In addition to our internal research programs, Entelos partners with pharmaceutical and biotechnology organizations worldwide.

Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc.

All other trademarks are the property of their registered owners.

Contact Information

  • Contacts:
    Entelos, Inc.
    Barry Sudbeck
    Email Contact
    Tel: +1.650.572.5479

    McKinney Chicago
    Alan Zachary
    Email Contact
    +1.312.944.6784 ext. 316